British medicine producer GSK on Monday noted that it is going to purchase US biopharmaceutical firm IDRx for up to USD1.15 billion. The Boston-originated biotechnology company is producing ...

Welcome to Day 2 of the J.P. Morgan Healthcare Conference 2025 in San Francisco. | Welcome to Day 2 of the J.P. Morgan ...

London: GSK plc has announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, ...

Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...

THOUSANDS of holidaymakers face woes due to engine troubles on five British Airways jets. The airline axed flights from ...

Major pharmaceutical companies like GSK, Eli Lilly, and Johnson & Johnson are engaging in multi-billion dollar acquisitions ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

Analysts say the deal, which would give Biogen full control over the drug Zurzuvae, could be a smart financial move. Yet it's ...

And GSK said it would pay up to $1.15 billion privately-held IDRx, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of GIST, which stands for Gastrointestinal ...

British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare ...

GSK plc has agreed to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing ...

Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...